2-((2-Methyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-yl)amino)acetic acid

Catalog No. :
ACUMGX913
CAS No. :
878709-00-3
Molecular Formula :
C13H15N3O2S
Molecular Weight :
277.35

IUPAC Name:(2-methyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-yl)glycine

2-((2-Methyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-yl)amino)acetic acid structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g95%$441.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name2-((2-Methyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-yl)amino)acetic acid
IUPAC Name(2-methyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-yl)glycine
MDL No.MFCD06255215
Molecular FormulaC13H15N3O2S
Molecular Weight277.35
SMILESO=C(O)CNC1=C(C2=C(CCCC2)S3)C3=NC(C)=N1
InChI KeySCFBRDZXXMMWMT-UHFFFAOYSA-N
SynonymTIMTEC-BB SBB012197;(2-METHYL-5,6,7,8-TETRAHYDRO-BENZO[4,5]THIENO[2,3-D]PYRIMIDIN-4-YLAMINO)-ACETIC ACID;ASINEX-REAG BAS 12290459;(2-Methyl-5,6,7,8-tetrahydro-benzo[4,5]thieno-[2,3-d]pyrimidin-4-ylamino)-acetic;2-[(2-methyl-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d]pyrimidin-4-yl)azaniumyl]acetate;Glycine, N-(5,6,7,8-tetrahydro-2-methyl[1]benzothieno[2,3-d]pyrimidin-4-yl)-
CAS No.878709-00-3

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H317-H319
Precautionary Statement(s)
P280-P305+P351+P338

Synthetic Route by SureRoute

1. ACUMGX913 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACUMGX913 route product structure diagram
    ACUMGX913878709-00-3
Inquiry

2. ACUMGX913 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACUMGX913 route product structure diagram
    ACUMGX913878709-00-3
Inquiry

Comments (0)